Aleksander Krag on the utility of PEth for subclassifying individuals at risk of steatotic liver disease
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Aleksander Krag on the utility of PEth for subclassifying individuals at risk of steatotic liver disease
-
Narrated by:
-
By:
Summary
Steatotic liver disease labels hinge on alcohol intake, but self-report is often inaccurate. In this episode, Aleksander Krag (Odense University Hospital) discusses a large Danish study using phosphatidylethanol (PEth), a direct blood biomarker of recent drinking, showing substantial underestimation and potential reclassification from MASLD to MetALD/ALD.
Click here to read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00187-6/fulltext
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.
You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv